Janssen and ViiV's monthly injectable HIV combo proves non-inferior to daily standard of care

It was shown that HIV patients who had maintained viral suppression for at least six months, on a daily oral regimen comprised of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, maintained similar rates of viral suppression taking the combination of Janssen’s rilpivirine and ViiV’s cabotegravir compared to the standard regimen.

"These results offer new evidence that suggest this investigational, two-drug, once a month dosing regimen may reduce the impact of treatment on people’s lives," said Dr Wim Parys, Head of R&D, Global Public Health at Janssen. "This novel approach would signify a much-needed treatment evolution for people living with HIV, moving from dosing 365 days a year to just 12 times per year."

Full details of the findings of the trial will be presented at an upcoming scientific event. Janssen and ViiV’s regimen is currently not approved for use anywhere in the world.

-------------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.